We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+26.9%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$91.8M
Cap. Flow
-$24.1M
Cap. Flow %
-2.3%
Top 10 Hldgs %
32.3%
Holding
111
New
20
Increased
23
Reduced
56
Closed
11

Top Buys

Rank Stock Value
1
MASI
Masimo
MASI
+$28.6M
2
DXCM icon
DexCom
DXCM
+$26.9M
3
EYPT icon
EyePoint Inc
EYPT
+$15.4M
4
WAT icon
Waters Corp
WAT
+$15.4M
5
MTD icon
Mettler-Toledo International
MTD
+$15.3M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17.7M
2
BIIB icon
Biogen
BIIB
+$15.5M
3
DHR icon
Danaher
DHR
+$11.4M
4
CSTL icon
Castle Biosciences
CSTL
+$10.5M
5
VRDN icon
Viridian Therapeutics
VRDN
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$71.5B
$47.7M 4.54%
500,529
+66,152
+15% +$6.49M
PODD icon
2
Insulet
PODD
$9.79B
$40M 3.81%
140,860
+24,622
+21% +$7.7M
DXCM icon
3
DexCom
DXCM
$32B
$39M 3.71%
587,475
+415,847
+242% +$26.9M
SYK icon
4
Stryker
SYK
$130B
$37.1M 3.53%
105,472
+41,364
+65% +$15.1M
CVS icon
5
CVS Health
CVS
$122B
$35.7M 3.4%
450,212
+70,726
+19% +$5.58M
MCK icon
6
McKesson
MCK
$101B
$29.8M 2.84%
36,355
+7,813
+27% +$6.38M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$28.6M 2.72%
1,768,508
+33,505
+2% +$444K
MBX
8
MBX Biosciences
MBX
$3.27B
$27.9M 2.66%
885,639
+112,335
+15% +$2.73M
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$5.93B
$27.4M 2.61%
665,208
-6,384
-1% -$256K
MASI
10
DELISTED
Masimo
MASI
$26M 2.48%
+200,000
New +$28.6M
LIVN icon
11
LivaNova
LIVN
$4.2B
$25.3M 2.41%
410,912
+135,101
+49% +$7.72M
TERN
12
DELISTED
Terns Pharmaceuticals
TERN
$25.1M 2.39%
620,877
-313,883
-34% -$7.25M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.67B
$24.5M 2.33%
788,076
-366,411
-32% -$10M
RCUS icon
14
Arcus Biosciences
RCUS
$3.64B
$23.1M 2.2%
968,602
+315,922
+48% +$6.45M
UPB
15
Upstream Bio Inc
UPB
$395M
$22.7M 2.16%
834,559
-8,943
-1% -$223K
QGEN icon
16
Qiagen
QGEN
$8.72B
$22.2M 2.12%
494,351
-5,808
-1% -$269K
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
$21.2M 2.02%
1,487,283
-200,035
-12% -$1.97M
EYPT icon
18
EyePoint Inc
EYPT
$1.2B
$19.9M 1.89%
+1,088,033
New +$15.4M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$29.3B
$19M 1.81%
47,703
-39,987
-46% -$17.7M
NBIX icon
20
Neurocrine Biosciences
NBIX
$16.6B
$16.3M 1.55%
114,712
-27,110
-19% -$3.93M
WAT icon
21
Waters Corp
WAT
$39.9B
$15.9M 1.52%
+41,899
New +$15.4M
MTD icon
22
Mettler-Toledo International
MTD
$28.6B
$15.3M 1.46%
+10,988
New +$15.3M
MLYS icon
23
Mineralys Therapeutics
MLYS
$2.41B
$14.9M 1.42%
410,249
-45,274
-10% -$1.82M
STOK icon
24
Stoke Therapeutics
STOK
$2.11B
$13.7M 1.3%
430,155
+180,155
+72% +$5.42M
A icon
25
Agilent Technologies
A
$41.2B
$13.6M 1.3%
+100,000
New +$14.4M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Parkman Healthcare Partners held 111 positions worth $1.05B, up 9.6% from $959M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q4 2025 filing shows 20 new, 23 increased, 56 reduced and 11 closed positions. Its largest new stake was Masimo: 200,000 shares worth $26M. The largest sale was Alnylam Pharmaceuticals, an estimated $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2025 buy was Masimo: 200,000 shares worth $26M.
  • Parkman Healthcare Partners added most to DexCom in Q4 2025, an estimated $26.9M increase.
  • Parkman Healthcare Partners's biggest Q4 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $17.7M.
  • Parkman Healthcare Partners fully exited United Therapeutics in Q4 2025, selling an estimated $9.22M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $1.05B portfolio in Q4 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 11 in Q4 2025.
  • Parkman Healthcare Partners's portfolio value rose 9.6% quarter-over-quarter to $1.05B.

Based on Parkman Healthcare Partners's 13F filing for Q4 2025, filed 17 Feb 2026.